Prophylactic use of tranexamic acid for decreasing the blood loss in elective cesarean section: A placebo-controlled randomized clinical trial.


Journal

Journal of gynecology obstetrics and human reproduction
ISSN: 2468-7847
Titre abrégé: J Gynecol Obstet Hum Reprod
Pays: France
ID NLM: 101701588

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 12 07 2020
revised: 29 10 2020
accepted: 03 11 2020
pubmed: 23 11 2020
medline: 21 10 2021
entrez: 22 11 2020
Statut: ppublish

Résumé

Tranexamic acid is used as a known treatment of post-partum hemorrhage both in natural vaginal deliveries and cesarean sections, but its use in elective cesarean as a prophylactic measure to decrease the blood loss is not so common. This clinical trial evaluates the efficacy and safety of tranexamic acid in decreasing the bleeding in women undergoing elective cesarean section. 200 term singleton pregnant women who were scheduled for elective cesarean section were randomized to 2 groups and received a bolus of 1 gm tranexamic acid if body weight was <90 kg and 1.5 g if body weight was >90 kg diluted in 15 ml of 5% dextrose intravenously, or 5 ml of distilled water in 15 ml of 5% dextrose as placebo (before skin incision). Intra-operative and post-operative blood loss and hemoglobin levels were compared. Tranexamic acid decreased the mean blood loss by 25.3 % in our studied women. Mean volume of intra-operative blood loss was 391.1 (±67.4) ml in tranexamic acid group and 523.8 (±153.4) ml in control group which was statistically significant lesser with a 132.7 ml difference. Rate of >1000 ml and >500 ml bleeding and need to blood transfusion were also statistically significant lower in tranexamic acid group., mean hemoglobin level was statistically significant lower in placebo group than tranexamic acid group (11.77 ± 0.50 versus 11.31 ± 0.56) 6 h after cesarean section. No adverse reaction was documented. Prophylactic use of intravenous tranexamic acid decreases the blood loss safely in women undergoing elective cesarean section.

Identifiants

pubmed: 33221559
pii: S2468-7847(20)30343-3
doi: 10.1016/j.jogoh.2020.101973
pii:
doi:

Substances chimiques

Antifibrinolytic Agents 0
Tranexamic Acid 6T84R30KC1

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

101973

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors report no declarations of interest.

Auteurs

Zahra Naeiji (Z)

Preventive Gynecology Research Center (PGRC); Department of Gynecology and Obstetrics, Shahid Beheshti University of Medical Science (SBUMS), Tehran, Iran. Electronic address: Zahranaeiji98@yahoo.com.

Negar Delshadiyan (N)

Gynecology and Obstetrics Resident, Shahid Beheshti University of Medical Science (SBUMS), Iran.

Sorayya Saleh (S)

Department of Gynecology and Obstetrics, Shahid Beheshti University of Medical Science (SBUMS), Tehran, Iran. Electronic address: soraya_saleh2000@yahoo.co.uk.

Atefeh Moridi (A)

Department of Gynecology and Obstetrics, Shahid Beheshti University of Medical Science (SBUMS), Tehran, Iran. Electronic address: Moridi59@gmail.com.

Nayereh Rahmati (N)

Gynecology and Obstetrics Fellow, Shahid Beheshti University of Medical Science (SBUMS), Iran. Electronic address: N136054@yahoo.com.

Marzieh Fathi (M)

Iran University of Medical Sciences (IUMS), Iran. Electronic address: marziehfathi@yahoo.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH